GPP
SLDB icon

Great Point Partners’s Solid Biosciences SLDB Stock Holding History

Great Point Partners’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-13,333
Closed -$1.84M – 40
2019
Q1 		$1.84M Buy
+13,333
New +$3.34M 0.18% 36

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Great Point Partners's SLDB Position: Q4 2023 in Review

Great Point Partners sold out of Solid Biosciences (SLDB) in Q4 2023, closing a stake of 450,403 shares — an estimated $1.14M sold.

Great Point Partners first reported a position in SLDB in Q1 2023 and held it in 3 quarters. The position peaked at $3.06M in Q2 2023. 39 funds tracked by Wall St. Rank hold SLDB as of Q4 2023.

  • Great Point Partners reported no remaining Solid Biosciences position as of Q4 2023 after selling out during the quarter.
  • Great Point Partners sold 450,403 Solid Biosciences shares in Q4 2023, an estimated $1.14M.
  • Great Point Partners first reported a position in Solid Biosciences in Q1 2023 and held it in 3 quarters.
  • Great Point Partners's Solid Biosciences position peaked at $3.06M in Q2 2023.
  • 39 funds tracked by Wall St. Rank held Solid Biosciences as of Q4 2023.

Based on Great Point Partners's 13F filing for Q4 2023, filed 14 Feb 2024.